<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291497</url>
  </required_header>
  <id_info>
    <org_study_id>HPP-Study</org_study_id>
    <nct_id>NCT02291497</nct_id>
  </id_info>
  <brief_title>Burden of Disease in Hypophosphatasia (HPP)</brief_title>
  <official_title>Non-interventional, Prospective, Single-center Investigation With Exploratory Data Analysis to Delineate the Variability and Frequency of Symptoms and Disease Manifestations in Adult HPP Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypophosphatasia (HPP) is a rare, inherited metabolic disease caused by inactivating&#xD;
      mutations in the Alkaline Phosphatase (ALPL) gene, coding for the Tissue-nonspecific alkaline&#xD;
      phosphatase (TNAP). Penetrance and disease severity is very heterogenous, ranging from&#xD;
      stillbirth to adult-onset manifestations. Especially the latter are again characterized by an&#xD;
      extremely broad spectrum of symptoms. This scope of variability makes it difficult to&#xD;
      attribute individual patients' symptoms to the disease and distinguish them from HPP&#xD;
      independent health issues. Especially in adult HPP patients, musculoskeletal problems,&#xD;
      including (fragility-) fractures / bone bruise, joint pain, reduced mobility, muscular&#xD;
      weakness and pain and reduced muscular endurance appear to reflect the prevailing burden of&#xD;
      disease, especially with respect these patients dis-abilities of daily life.&#xD;
&#xD;
      To expand current knowledge of the natural history of the disease as well as on disease&#xD;
      specific musculoskeletal deficits in HPP, all adult patients with established Diagnosis of&#xD;
      HPP known at the Orthopedic Institute, University of Würzburg, will be offered to participate&#xD;
      in a single, multimodal assessment of their disease history, current symptoms and&#xD;
      disabilities, lab evaluations and clinical and technical analysis of their musculoskeletal&#xD;
      status and capabilities.&#xD;
&#xD;
      Patients will be invited to a day long visit to the clinic in order to perform the following&#xD;
      assessments:&#xD;
&#xD;
      A) Epidemiologic / anamnestic information B) Physical examination C) Structured&#xD;
      questionnaires D) Laboratory examinations E) Clinical functional testing F) Technical&#xD;
      Examinations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequencies of main disease symptoms and main disease manifestations</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">114</enrollment>
  <condition>Hypophosphatasia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be stored till 2031&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        see &quot;Eligibility Criteria&quot;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males and females (age ≥ 18 years)&#xD;
&#xD;
          -  Established diagnosis of Hypophosphatasia&#xD;
&#xD;
          -  Reduced Serum/Plasma ALP (Alkaline phosphatase)-Activity below age and sex specific&#xD;
             reference range of the respective test kit applied (measured at least twice with a&#xD;
             minimum 4 week interval)&#xD;
&#xD;
          -  At least one of the items below:&#xD;
&#xD;
               -  Genetically secured ALPL-Mutation&#xD;
&#xD;
               -  Elevated PLP (Pyridoxal 5-Phosphate) (urine or serum), above ULN (Upper level of&#xD;
                  normal)&#xD;
&#xD;
               -  Symptoms of the disease&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current / previous treatment with Asfotase alfa&#xD;
&#xD;
          -  Current participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Unit, Orthopaedische Klinik Koenig-Ludwig-Haus, Lehrstuhl der Universitaet Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bavaria</state>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>November 5, 2016</last_update_submitted>
  <last_update_submitted_qc>November 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuerzburg University Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Lothar Seefried</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

